Valuation: Pluristem Therapeutics Inc.

Market Cap 12.22M 10.85M 10.15M 9.2M 17.38M 1.18B 17.5M 122M 47.43M 601M 45.87M 44.89M 1.93B P/E 2025
-1.39x
P/E 2026 -0.85x
Enterprise Value 39.33M 34.91M 32.67M 29.61M 55.93M 3.79B 56.33M 392M 153M 1.93B 148M 144M 6.22B EV / Sales 2025
39,078,124x
EV / Sales 2026 48,878,101x
Free-Float
57.48%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer 54 2017-03-28
Director of Finance/CFO 42 2022-11-30
Chief Operating Officer - 2024-12-31
Director TitleAgeSince
Director/Board Member 54 2015-01-31
Director/Board Member 56 2021-01-05
Director/Board Member 64 2021-05-31
Change 5-day change 1-year change 3-year change Capi.($)
+11.70%-24.18% - - 12.78M
+4.16%+4.16%+49.37%+94.17% 74.31B
+2.76%-1.16%+23.05%+83.03% 56.95B
+0.24%-1.37%+4.08%+37.22% 48.3B
-3.76%-2.25%+329.09%+698.20% 44.51B
-2.30%-3.35%+26.81%+30.88% 43.8B
+0.31%-0.68%+5.30%+108.64% 41.12B
-0.11%+2.30%+9.19%+58.68% 31.07B
+4.51%+8.43%+37.27%+34.97% 28.97B
-1.96%-2.88%-8.97%-13.92% 24.53B
Average +1.55%-0.78%+52.80%+125.76% 43.73B
Weighted average by Cap. +0.77%-0.94%+56.83%+134.46%

Financials

2025 2026
Net sales 1.34 1.19 1.11 1.01 1.9 128.79 1.91 13.33 5.18 65.7 5.01 4.91 211.21 1.02 0.9 0.84 0.77 1.44 97.94 1.46 10.14 3.94 49.96 3.81 3.73 160.62
Net income -22.58M -20.05M -18.76M -17M -32.11M -2.18B -32.35M -225M -87.64M -1.11B -84.77M -82.95M -3.57B -23.82M -21.15M -19.79M -17.94M -33.87M -2.3B -34.12M -238M -92.44M -1.17B -89.41M -87.5M -3.77B
Net Debt 13.44M 11.93M 11.16M 10.12M 19.11M 1.3B 19.25M 134M 52.14M 661M 50.44M 49.36M 2.12B 27.11M 24.07M 22.52M 20.41M 38.55M 2.61B 38.83M 270M 105M 1.33B 102M 99.58M 4.29B
Logo Pluristem Therapeutics Inc.
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Employees
-